2,537 Shares in Elevance Health, Inc. $ELV Bought by 111 Capital

111 Capital bought a new stake in shares of Elevance Health, Inc. (NYSE:ELV) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 2,537 shares of the company’s stock, valued at approximately $820,000.

Several other institutional investors have also added to or reduced their stakes in ELV. Hantz Financial Services Inc. boosted its stake in Elevance Health by 116.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 277 shares of the company’s stock worth $108,000 after purchasing an additional 149 shares in the last quarter. Pinnacle Associates Ltd. raised its holdings in shares of Elevance Health by 17.3% in the second quarter. Pinnacle Associates Ltd. now owns 3,452 shares of the company’s stock worth $1,343,000 after buying an additional 508 shares during the last quarter. GHP Investment Advisors Inc. lifted its stake in shares of Elevance Health by 6.4% during the second quarter. GHP Investment Advisors Inc. now owns 14,155 shares of the company’s stock worth $5,506,000 after buying an additional 853 shares during the period. Mission Wealth Management LP grew its holdings in shares of Elevance Health by 2.2% during the second quarter. Mission Wealth Management LP now owns 3,281 shares of the company’s stock valued at $1,276,000 after buying an additional 71 shares during the last quarter. Finally, South Dakota Investment Council increased its position in shares of Elevance Health by 64.9% in the 2nd quarter. South Dakota Investment Council now owns 43,053 shares of the company’s stock valued at $16,746,000 after acquiring an additional 16,939 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ELV. Weiss Ratings cut Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, February 2nd. Wolfe Research set a $425.00 price target on shares of Elevance Health and gave the stock an “outperform” rating in a research report on Thursday, January 8th. TD Cowen restated a “buy” rating on shares of Elevance Health in a research note on Wednesday, November 26th. Zacks Research raised shares of Elevance Health from a “strong sell” rating to a “hold” rating in a report on Thursday, November 6th. Finally, UBS Group set a $400.00 target price on shares of Elevance Health in a report on Thursday, January 29th. Twelve equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Elevance Health has an average rating of “Moderate Buy” and an average target price of $390.55.

Elevance Health Price Performance

Shares of NYSE ELV opened at $293.99 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54. The stock has a market capitalization of $64.89 billion, a price-to-earnings ratio of 11.70, a PEG ratio of 1.77 and a beta of 0.51. The firm’s 50 day simple moving average is $349.22 and its 200-day simple moving average is $335.98. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $458.75.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be paid a dividend of $1.72 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $6.88 annualized dividend and a yield of 2.3%. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is currently 27.23%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.